Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
COVID-19 Rapid Antigen Self-Test, COVI-Go, receives FDA Emergency Use Authorization for Home Use
Mologic, the US subsidiary of Global Access Diagnostics (GADx), a leading developer of lateral flow […]
Nexus Pharmaceuticals Announces Launch of Sterile Vial Product Line
Nexus Pharmaceuticals announced the launch of its new product line – Sterile Vials from Nexus […]
Xspray Pharma Partners with EVERSANA for the Treatment of Chronic Myeloid Leukemia (CML) and Acute Lymphatic Leukemia (ALL)
Xspray Pharma AB has signed an agreement with EVERSANA to support the U.S. launch and commercialization of […]
Mezzion Pharma Submits Protocol for Confirmatory Pivotal Phase 3 Trial ("FUEL-2") in Fontan Subjects
Mezzion Pharma has submitted a confirmatory pivotal Phase 3 Clinical Trial in Fontan subjects to […]
FDA Accepts Orasis Pharmaceuticals' New Drug Application for CSF-1 for the Treatment of Presbyopia
Orasis Pharmaceuticals, an emerging ophthalmic pharmaceutical company focused on developing a unique eye drop to […]
Azafaros Receives Additional Regulatory Designations for AZ-3102 from FDA, EMA and MHRA
Azafaros today announced its progress in ongoing interactions with Health Authorities regarding its lead drug […]
Astellas Provides Update on Fezolinetant New Drug Application in U.S.
Astellas Pharma has announced the US Food and Drug Administration (FDA) notified the company that […]
Terumo Blood and Cell Technologies' IMUGARD Platelet Pooling Set Cleared by FDA
Today, Terumo Blood and Cell Technologies have announced US Food and Drug Administration (FDA) clearance […]
Chiesi Global Rare Diseases Announces FDA Approval of Lamzede®(velmanase alfa-tycv) for Alpha-Mannosidosis
Chiesi Global Rare Diseases announced today that the US Food and Drug Administration (FDA) has […]
Axcella Announces FDA IND Clearance Supporting Regulatory Path to Registration of AXA1125 for Long COVID Fatigue
Axcella Therapeutics, a clinical-stage biotechnology company pioneering novel approaches to treating complex diseases using multi-targeted […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more